SelectQuote surges 17% on strong earnings beat By Investing.com

SelectQuote reported Q3 fiscal 2026 adjusted EPS of $0.11, beating the $0.02 consensus by $0.09, while revenue rose 6% year over year to $430.9 million, slightly below the $442.5 million estimate. Net income increased to $40.2 million from $26.0 million, and consolidated adjusted EBITDA improved to $44.6 million from $37.7 million. The company reaffirmed full-year revenue guidance of $1.61 billion to $1.71 billion and expects adjusted EBITDA of $90 million to $100 million, supporting a positive reaction in the shares.

Analysis

The market is likely underestimating how much of this beat is quality versus timing. The combination of a high acquisition-efficiency read-through and raised full-year EBITDA implies the model is not just benefiting from one-off claims or seasonal mix, but from tighter conversion economics that can persist if customer acquisition costs stay disciplined. That matters because in lead-gen-heavy healthcare intermediaries, margin inflection usually lags revenue by 1-2 quarters; the current setup suggests the company may be entering the favorable part of that cycle.

The second-order winner is any adjacent platform that can prove similar unit economics, while the loser is competitors still spending aggressively to buy growth in Medicare and prescription benefits. If SelectQuote can sustain this conversion, it may force a reset in valuation for other consumer-facing healthcare distribution names where the market has been paying for top-line growth rather than monetization efficiency. The bigger implication is that management is signaling confidence in pricing power and retention at a time when many investors expected utilization or mix pressure to cap margins.

The main risk is that this is a narrow beat in an environment where guidance may still prove too conservative on revenue if policy changes or channel mix shifts normalize. The stock’s move can continue for days if momentum buyers focus on EBITDA and cash flow, but over a 1-3 month horizon the key question is whether the margin outperformance is repeatable without incremental spend. If CAC drifts higher or conversion softens next quarter, the multiple expansion could unwind quickly because the market will have already priced in a cleaner operating model.

Consensus may be missing that the real asset here is not just the current quarter’s earnings power, but the option value of a higher-quality distribution franchise. If this quarter marks a sustained inflection in acquisition efficiency, SLQT should trade less like a cyclical marketing business and more like a recurring-fee healthcare platform. That rerating could be significant, but only if the next print confirms that the 6.7x revenue-to-CAC relationship is durable rather than promotional.

Key Decisions for Investors

• Go long SLQT on a 1-3 month horizon, using strength after the gap-up only if it holds above the post-earnings breakout level; target a continuation move as the market reprices the EBITDA/cash flow trajectory, with risk defined by any reversal below the earnings-day low.
• Buy SLQT Jan/Apr upside calls or call spreads to express near-term momentum while capping downside; the thesis is that multiple expansion can persist for 1-2 quarters if management delivers another clean beat and raises guidance again.
• Pair long SLQT vs short a slower-growing healthcare distribution/lead-gen peer basket over the next quarter; the trade benefits if capital rotates toward unit-economics winners and away from names still funding growth with weaker conversion.
• If already long, trim into any further 15-20% rally unless the next monthly or quarterly operating commentary confirms CAC discipline; the stock is likely to get punished hard on even modest signs of acquisition inefficiency.
• Set a catalyst watch for the next update on Medicare and prescription mix; if management reiterates or improves margin guidance, add on pullbacks, but if revenue growth slows while EBITDA holds, treat that as a sign the rerating may have run ahead of fundamentals.